Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life

• প্রধান লেখক: Tessa Hosman (লেখক), Roy van Heesbeen (লেখক), Arangassery Rosemary Bastian (লেখক), Weihong Hu (লেখক), Christy Comeaux (লেখক), Nynke Ligtenberg (লেখক), Bart van Montfort (লেখক), Benoît Callendret (লেখক), Esther Heijnen (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

ABSTRACTThis study assessed three Ad26.RSV.preF/RSV preF protein combinations, combining different Ad26.RSV.preF doses and naturally aged preF protein, representing the expected critical vaccine quality attributes close to release, around intermediate shelf-life (ISL) and near-presumed end-of-shelf-...